Gamida Cell Appoints Terry Coelho As CFO, Effective Immediately
Portfolio Pulse from Benzinga Newsdesk
Gamida Cell Ltd. (NASDAQ:GMDA) has appointed Terry Coelho as CFO, effective immediately, replacing Shai Lankry who will leave the company on June 2. Coelho brings over 35 years of experience and currently serves as an independent director on the boards of First Wave BioPharma (NASDAQ:FWBI) and HOOKIPA Pharma (NASDAQ:HOOK).
May 22, 2023 | 12:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gamida Cell appoints Terry Coelho as CFO, bringing extensive experience to the company as it transitions to a commercial-stage company.
Terry Coelho's appointment as CFO of Gamida Cell is likely to have a positive short-term impact on GMDA's stock price. Her extensive experience in finance and leadership roles at emerging growth and global companies will be valuable as Gamida Cell transitions from a clinical to a commercial-stage company. This change in leadership is expected to support the company's growth and expansion.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEUTRAL IMPACT
Terry Coelho, an independent director on the board of First Wave BioPharma, has been appointed as CFO of Gamida Cell.
Terry Coelho's appointment as CFO of Gamida Cell is not expected to have a significant short-term impact on FWBI's stock price. Although she serves as an independent director on the board of First Wave BioPharma, her new role at Gamida Cell is unlikely to directly affect FWBI's operations or performance.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Terry Coelho, an independent director on the board of HOOKIPA Pharma, has been appointed as CFO of Gamida Cell.
Terry Coelho's appointment as CFO of Gamida Cell is not expected to have a significant short-term impact on HOOK's stock price. Although she serves as an independent director on the board of HOOKIPA Pharma, her new role at Gamida Cell is unlikely to directly affect HOOK's operations or performance.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50